These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18257606)

  • 1. Current and future therapeutic options in the management of invasive aspergillosis.
    Krishnan-Natesan S; Chandrasekar PH
    Drugs; 2008; 68(3):265-82. PubMed ID: 18257606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pharmacological opportunities for the treatment of invasive mould diseases.
    Ledoux MP; Toussaint E; Denis J; Herbrecht R
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of invasive fungal infections: a role for polyenes.
    Chandrasekar P
    J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of drug-resistant Aspergillus infection.
    Aigner M; Lass-Flörl C
    Expert Opin Pharmacother; 2015; 16(15):2267-70. PubMed ID: 26328502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
    Lellek H; Waldenmaier D; Dahlke J; Ayuk FA; Wolschke C; Kröger N; Zander AR
    Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacies and clinical roles of new antifungal agents].
    Tokimatsu I; Kadota J
    Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal Therapies for Aspergillus spp.: Present and Future.
    Eschenauer GA
    Semin Respir Crit Care Med; 2024 Feb; 45(1):61-68. PubMed ID: 38151025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive Aspergillosis: Epidemiology, Clinical Aspects, and Treatment.
    Gregg KS; Kauffman CA
    Semin Respir Crit Care Med; 2015 Oct; 36(5):662-72. PubMed ID: 26398533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of new antifungal agents.
    Kauffman CA
    Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antifungal therapy update: new drugs and medical uses].
    Fortún J
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():38-44. PubMed ID: 22305668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
    Steinbach WJ
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):203-10. PubMed ID: 16181140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in combination therapy for invasive aspergillosis].
    Luo L; Tong Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):41-4. PubMed ID: 24694973
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
    Ullmann AJ; Aguado JM; Arikan-Akdagli S; Denning DW; Groll AH; Lagrou K; Lass-Flörl C; Lewis RE; Munoz P; Verweij PE; Warris A; Ader F; Akova M; Arendrup MC; Barnes RA; Beigelman-Aubry C; Blot S; Bouza E; Brüggemann RJM; Buchheidt D; Cadranel J; Castagnola E; Chakrabarti A; Cuenca-Estrella M; Dimopoulos G; Fortun J; Gangneux JP; Garbino J; Heinz WJ; Herbrecht R; Heussel CP; Kibbler CC; Klimko N; Kullberg BJ; Lange C; Lehrnbecher T; Löffler J; Lortholary O; Maertens J; Marchetti O; Meis JF; Pagano L; Ribaud P; Richardson M; Roilides E; Ruhnke M; Sanguinetti M; Sheppard DC; Sinkó J; Skiada A; Vehreschild MJGT; Viscoli C; Cornely OA
    Clin Microbiol Infect; 2018 May; 24 Suppl 1():e1-e38. PubMed ID: 29544767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echinocandins: a wealth of choice--how clinically different are they?
    Zaas AK
    Curr Opin Infect Dis; 2008 Aug; 21(4):426-32. PubMed ID: 18594297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
    Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
    Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
    Ibrahim AS; Gebremariam T; Luo G; Fu Y; French SW; Edwards JE; Spellberg B
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1768-70. PubMed ID: 21263057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary aspergillosis: recent advances.
    Thompson GR; Patterson TF
    Semin Respir Crit Care Med; 2011 Dec; 32(6):673-81. PubMed ID: 22167395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus.
    Wiederhold NP; Najvar LK; Jaramillo R; Olivo M; Wickes BL; Catano G; Patterson TF
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspofungin for treatment of invasive aspergillus infections.
    Heinz WJ; Einsele H
    Mycoses; 2008; 51 Suppl 1():47-57. PubMed ID: 18471161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.